Skip to main content
Morepen Laboratories Ltd. logo

Morepen Laboratories Ltd. — Investor Relations & Filings

Ticker · MOREPENLAB ISIN · INE083A01026 LEI · 335800OJZDFHFQJ4HP35 BSE.NS Manufacturing
Open in API
Filings indexed 1,660 across all filing types
Latest filing 2024-02-19 Regulatory Filings
Country IN India
Listing BSE.NS MOREPENLAB

About Morepen Laboratories Ltd.

https://www.morepen.com

Morepen Laboratories Ltd. is a research-led company specializing in the development, manufacturing, and marketing of Active Pharmaceutical Ingredients (APIs), home diagnostic devices, and finished formulations. The company maintains a significant global presence, exporting high-quality APIs such as Loratadine, Montelukast, Atorvastatin, and Fexofenadine to numerous international markets. Its diagnostic division, branded as Dr. Morepen, is a prominent player in the home healthcare segment, offering a wide range of products including digital glucometers, blood pressure monitors, and nebulizers. Morepen operates manufacturing facilities compliant with international regulatory standards, including USFDA approvals. The company focuses on leveraging its R&D capabilities to deliver healthcare solutions and maintains a diverse portfolio across various therapeutic areas including cardiovascular, anti-diabetic, and anti-asthmatic treatments.

Recent filings

Filing Released Lang Actions
Board Meeting — MOREPEN LABORATORIES LIMITED has informed the Exchange about Board Meeting to be held on 22-Feb-2024 to consider and approve Fund raising/Other business.
Regulatory Filings
2024-02-19 English
Board Meeting — Fund Raising/Other business matters
Capital/Financing Update Classification · 95% confidence The document is a notification dated 19/02/2024 from Morepen Laboratories Limited addressed to stock exchanges regarding a forthcoming Board of Directors meeting scheduled for 22/02/2024. The purpose of the meeting includes evaluating proposals for fund raising through issuance of securities and approving the notice for an Extraordinary General Meeting or Postal Ballot to seek shareholder approval for the fund raising. The document also mentions the closure of the trading window for insiders in compliance with insider trading regulations. The content is an announcement of an upcoming board meeting and related agenda items, specifically about capital raising proposals and shareholder meeting notices. It does not contain any financial statements, detailed financial data, or the actual report or results of the meeting. The document length is 3490 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document is best classified as a Capital/Financing Update (CAP) because it informs about proposed financing activities and related board meeting agenda, but it is not the actual report or approval notice itself.
2024-02-19 English
MOREPEN LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 22/02/2024 ,inter alia, to consider and approve raising of funds and ....
Board/Management Information Classification · 95% confidence The document is a notification dated 19/02/2024 from Morepen Laboratories Limited addressed to stock exchanges regarding a forthcoming Board of Directors meeting scheduled for 22/02/2024. The purpose of the meeting includes evaluating proposals for fundraising through issuance of securities and approving the notice for an Extraordinary General Meeting or Postal Ballot to seek shareholder approval for the fundraising. The document also mentions the closure of the trading window for insiders in compliance with the company's insider trading code. The content is an announcement of an upcoming board meeting and related agenda items, not the actual meeting minutes, financial report, or detailed presentation. It is a prior intimation of a board meeting and fundraising proposal, which fits the category of Board/Management Information (MANG). The document length is short (3490 characters) and does not contain financial data or detailed reports, so it is not an Annual Report, Interim Report, or Capital/Financing Update itself, but an announcement related to management decisions and board activities.
2024-02-19 English
Please find enclosed details of issue of letter of confirmation for duplicate shares.
Regulatory Filings
2024-02-14 English
Loss of Share Certificates
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges regarding the issuance of letters of confirmation against duplicate share certificates. It references compliance with SEBI regulations and a circular, but it does not contain financial statements, management discussion, or detailed financial data. The document is short (1924 characters) and serves as an informational announcement rather than a full report. It is not an annual report, interim report, earnings release, or any detailed financial or governance report. It is also not a proxy solicitation, voting result, or capital change announcement. The content fits best as a Regulatory Filing (RNS) because it is a compliance-related announcement that does not fit other specific categories.
2024-02-14 English
Loss of Share Certificates
Regulatory Filings
2024-02-06 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.